“Project Open DIPG” Study Focused on HDAC Inhibitors

This multi-institutional Project Open DIPG study uses state-of-the-art technology to determine the potency of candidate drugs belonging to the novel class of molecules called HDAC inhibitors.

This grant enables researchers to:

• Compare the treatments’ effects on its own versus in combination with other types of treatments
• Study the cancer cells’ molecular functionality at the DNA and protein levels
• Determine animal model survival rates and duration

Project Open DIPG is a joint venture by the Pacific Pediatric Neuro-Oncology Consortium, a previous PBTF Opportunity Grant awardee, and the Children’s Brain Tumor Tissue Consortium.

The research builds on PNOC’s clinical trial portfolio through biospecimen collection, genomic sequencing, and an experimental animal model systems approach supported by CBTTC. The tissue samples will be added to CBTTC’s biorepository, and data from preclinical drug testing in DIPG tumor samples will be deposited into the CAVATICA platform.